Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-TROP2 monoclonal antibody-Tub196 conjugate JS108

An antibody-drug conjugate (ADC) composed of a recombinant humanized monoclonal antibody against tumor-associated antigen (TAA) trophoblast cell surface protein 2 (trophoblast antigen 2; calcium signal transducer 2; TROP2; TROP-2; TACSTD2; GA733-1; M1S1) conjugated, via a 2,3-disubstituted long side chain hydrolysis-resistant linker, to the tubulysin B analog Tub196, with potential antineoplastic activity. Upon administration of the anti-TROP2 monoclonal antibody-Tub196 conjugate JS108, the anti-TROP2 antibody targets and binds to TROP2 expressed on tumor cells. Upon cellular uptake, the cytotoxic tubulysin B analog binds to tubulin, thereby affecting microtubule assembly and disassembly dynamics. This inhibits microtubule polymerization, which blocks cell division and results in G2/M phase arrest, tumor cell apoptosis and a decrease in proliferation of TROP2-expressing tumor cells. TROP2 is a transmembrane protein overexpressed in various tumors. Its expression is associated with enhanced tumor aggressiveness, metastasis, drug resistance, increased tumor cell survival and poor prognosis.
Synonym:ADC JS108
anti-Trop-2 antibody-drug conjugate JS108
anti-TROP2 ADC JS108
anti-TROP2-Tub196 ADC JS108
Code name:JS 108
JS-108
JS108
Search NCI's Drug Dictionary